Zobrazeno 101 - 110
of 127
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
Lauren Peter, Evisa Gjini, Jerome Ritz, Indu Javeri, Wandi Zhang, William J. Lane, Zhuting Hu, Kai W. Wucherpfennig, David J. Bozym, Jon C. Aster, Anita Giobbie-Hurder, Shuqiang Li, Donna Neuberg, Nir Hacohen, Charles H. Yoon, Todd A. Carter, Kaliappanadar Nellaiappan, Heather Daley, Jonathan Stevens, Michael S. Seaman, Gad Getz, Jing Sun, David J. Lieb, Thomas Eisenhaure, Elizabeth I. Buchbinder, Derin B. Keskin, Edward F. Fritsch, Stacey Gabriel, Niall Lennon, Andres M. Salazar, Dan H. Barouch, Christina Chen, Adrienne M. Luoma, Oriol Olive, Eric S. Lander, Patrick A. Ott, Maegan Harden, Sachet A. Shukla, Scott J. Rodig, Catherine J. Wu
Publikováno v:
Nature. 555:402-402
Nature 547, 217–221 (2017); doi:10.1038/nature22991 In this Letter, the ‘Data availability’ section in the Methods should state ‘WES and RNA-seq data are deposited in dbGaP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 5 (2015)
Frontiers in Oncology, Vol 5 (2015)
The role of angiogenesis as a mediator of immune regulation in the tumor microenvironment has recently come into focus. Furthermore, emerging evidence indicates that immunotherapy can lead to immune-mediated vasculopathy in the tumor, suggesting that
Autor:
Elizabeth I, Buchbinder, Jeffrey A, Sosman, Donald P, Lawrence, David F, McDermott, Nikhil H, Ramaiya, Annick D, Van den Abbeele, Gerald P, Linette, Anita, Giobbie-Hurder, F Stephen, Hodi
Publikováno v:
Cancer. 121(22)
Patients with mucosal and acral melanomas have limited treatment options and a poor prognosis. Mutations of the KIT oncogene in these melanoma subtypes provide a potential therapeutic target.A multicenter phase 2 trial of sunitinib was conducted in p
Autor:
Julie Y, Tse, Brooke E, Walls, Hyemin, Pomerantz, Charles H, Yoon, Elizabeth I, Buchbinder, Andrew E, Werchniak, Fei, Dong, Christine G, Lian, Scott R, Granter
Publikováno v:
Journal of cutaneous pathology. 43(1)
Dermal melanocytosis refers to a spectrum of benign melanocytic proliferations that includes Mongolian spot, nevus of Ota and nevus of Ito. These lesions most commonly occur in persons of Asian or African descent and are often present at birth or dev
Publikováno v:
Clinical therapeutics. 37(4)
Purpose Melanoma is an aggressive malignancy that has a complex relationship with the host immune system. Immunotherapies have long been a mainstay of melanoma therapy, and advanced therapies continue to be effective in treating this disease. Immune
Autor:
Aislyn Schalck, Virginia Seery, Anita Giobbie-Hurder, Anasuya Gunturi, Ryan M. Merritt, Alireza Sepehr, David F. McDermott, James W. Mier, Ryan J. Sullivan, Donald P. Lawrence, Elizabeth I. Buchbinder, Keith T. Flaherty, A. John Iafrate, F. Stephen Hodi, Dennie Fredrick, Jennifer A. Wargo, Laleh Montaser-Kouhsari, Michael B. Atkins, Alexander Carlson, David J. Panka, Rachel Cohen
Publikováno v:
Molecular cancer therapeutics. 13(12)
BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treat
Publikováno v:
Nature Reviews Clinical Oncology. 13:77-78
In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immun
Autor:
Andrea Wang-Gillam, Mario Sznol, Keith T. Flaherty, Manish R. Patel, Filip Janku, David M. Hyman, Mary Varterasian, Elizabeth I. Buchbinder, Anna M. Varghese, Sapna Pradyuman Patel, Dean Welsch, Vicki L. Keedy, Ryan J. Sullivan, Antoni Ribas, Deborah Jean Lee Wong, Jeffrey R. Infante, Bob T. Li, Jeffrey A. Sosman, Anthony W. Tolcher, Mario E. Lacouture
Publikováno v:
Journal of Clinical Oncology. 35:2508-2508
2508 Background: Aberrant MAPK pathway activation is known to be an oncogenic driver in many solid tumors, making ERK inhibition an attractive therapeutic strategy. Ulixertinib is an oral ERK1/2 inhibitor that demonstrated potent activity in vitro an
Autor:
Donna Neuberg, Elizabeth I. Buchbinder, Kenneth A. Bauer, Federico Campigotto, Craig M. Kessler, Bruce Furie, Simon Mantha, Rachel P. Rosovsky, H. J. Lenz, Vidya Raghavan, Jonathan D. Eneman, Thomas Caughey, Howard A. Liebman, Jeffrey I. Zwicker, Andrea J. Bullock
Elevated levels of circulating tissue factor-bearing microparticles (TFMP) have been associated with an increased risk of developing venous thromboembolism (VTE) in cancer patients. We performed a randomized phase II study to evaluate the cumulative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::487ec5457dd6da7ce7b3e81a37fd1dd8
https://europepmc.org/articles/PMC3609903/
https://europepmc.org/articles/PMC3609903/
Autor:
Michael A. Davies, Richard W. Joseph, John A. Jakob, Alexander S. Parker, Ryan J. Sullivan, Patrick Hwu, Elizabeth I. Buchbinder, Ruchi G. Sharma, Roland L. Bassett, Jeanette E. Eckel-Passow, Michael B. Atkins, Ping Liu
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 35(9)
Ipilimumab improves overall survival (OS) in patients with metastatic melanoma including those previously treated with high-dose interleukin-2 (HD IL-2). The primary objective of this study was to determine if clinical response or progression-free su